Many men survive prostate cancer, but thousands of others — whose cancer spreads — inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life. Now, armed with a new $10 million grant, a multi-centre “dream team’’ of scientists is embarking on a groundbreaking undertaking into personalized medicine. The goal: to overcome therapeutic resistance in the disease and revolutionize treatment for patients with advanced prostate cancer.
Drs. Martin Gleave and Colin Collins part of new pan-Canadian prostate cancer networkA new pan-Canadian network of prostate cancer researchers formed by the Terry Fox Research Institute (TFRI) aims to address this need with approximately $4-million provided by the Terry Fox Foundation and the Canadian Partnership Against Cancer. The funding was announced today at the CHUM Research Centre (CRCHUM).
Vancouver Prostate Centre is proud to partner with Step Into Action to raise awareness of the critical role of early detection, and to raise funds for prostate cancer research.Dr. Riley Senft completed his cross-Canada run from Cape Spear to Vancouver as a personal quest to save the lives of future prostate cancer patients by educating men on the steps to early prostate cancer detection.
Focusing on early detection and disease preventionOver 150 clinicians, scientists, and staff will be pioneering new treatments and cures and working on disease prevention strategies in the new Robert H.N Ho Research Centre. The facility, adjacent to the Jack Bell Research Centre, is home to three internationally-recognized health research programs: the Centre for Hip Health and Mobility; the Ovarian Cancer Research Program, and an expansion of the Vancouver Prostate Centre.
Vancouver, B.C. – The Provincial Health Services Authority (PHSA) is pleased to announce that its Centre for Translational and Applied Genomics (CTAG) has been granted full accreditation status by the College of American Pathologists (CAP). CAP is the world’s largest association composed exclusively of pathologists certified by the American Board of Pathology and is widely considered the leader in laboratory quality assurance. CTAG, a division of PHSA Laboratories, is a self-funded translational research facility, focusing on cutting-edge research and development.
Vancouver, British Columbia — Two Vancouver researchers are tackling the deadliest forms of prostate cancer, the most commonly diagnosed male cancer in Canada, using a brand new field of genomics called computational chemogenomics. This new approach uses computer modeling in virtual 3D to predict how different chemicals or drugs will affect cancer tumours.The project, titled “Methods of Chemical Genomics” has received $324,000 in funding, with $161,500 from Genome BC and the rest from other partners including the Canadian Institutes of Health Research and the Vancouver Prostate Centre.
The Vancouver Prostate Centre today announced a one-year collaborative project with Novartis Pharmaceutical Corporation. The project will use cutting-edge technology to identify and validate the molecular targets that predict cancer sensitivity or insensitivity to specific inhibitors.
The results from a Phase II clinical trial of OGX-011, lead by Dr. Kim Chi, have been published in the Journal of Clinical Oncology. OGX-011 was developed at the Vancouver Prostate Centre, and is now moving to Phase III trials.Further details describing the development of OGX-011 were recently the subject of an article in the Vancouver Sun.
Two Vancouver-based “Centres of Excellence in Commercialization in Research” Leverage Resources and Expertise to Develop Anti-Cancer TherapeuticsVANCOUVER, BC – The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.“Knowing that our two organizations hold similar mandates, this collaboration with CDRD ensures that we are maximizing our resources to inc